Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial

What Was Tested

This randomized controlled trial paper looks at GHRH (Growth Hormone-Releasing Hormone).

Who Took Part

According to the abstract, 60 subjects were involved.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Treatment effect was determined by longitudinal linear mixed-effects modeling.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this GHRH (Growth Hormone-Releasing Hormone) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the subjects nor the staff measuring them knew who was on GHRH (Growth Hormone-Releasing Hormone), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with GHRH (Growth Hormone-Releasing Hormone) could be set against what happens without it.

Abdominal visceral adipose tissue (VAT) was assessed by abdominal computed tomography scan, and carotid intima-media thickness (cIMT) was assessed by ultrasound.

What Was Measured

PubMed files the paper under topics including Cardiovascular Diseases, Down-Regulation, Growth Hormone-Releasing Hormone, Human Growth Hormone, Intra-Abdominal Fat, Obesity, Abdominal and Risk Factors.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GHRH (Growth Hormone-Releasing Hormone) in 60 subjects.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.